Merck ( MRK) reported second-quarter adjusted earnings of 83 cents a share, topping the estimates of analysts of 77 cents a share.

Including restructuring charges and merger-related expenses, second-quarter earnings were 74 cents a share. Net income fell to $1.56 billion from $1.77 billion a year earlier.

Worldwide sales fell 3% to $5.9 billion in the quarter. Merck said excluding the impact of foreign exchange total revenue would have risen 3%. Analysts forecast sales of $5.84 billion.

In a statement Tuesday, Merck said earnings were driven by "strong growth" in its newest pharmaceutical products and in allergy drug Singulair.

Merck is expected to complete its merger with Schering-Plough in the fourth quarter. Schering-Plough saw its profit rise 48% in the quarter, as it recorded lower one-time costs.

Schering-Plough earned $633 million, or 38 cents a share, compared with $424 million, or 26 cents a share, in the same period a year ago. Excluding one-time items, profit rose to 46 cents a share from 45 cents a share, beating analyst estimates by a penny a share.
Copyright 2009 TheStreet.com Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. AP contributed to this report.

If you liked this article you might like

'Date' These Potential Biotech Winners

'Date' These Potential Biotech Winners

The 10 Stocks America's Biggest Hedge Funds Are Dumping Like Crazy

Why You Keep Cash on Hand; No Downside Conviction -- Jim Cramer's Top Thoughts